SEC	Form	4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligation may continue. See Instruction 1(b).
--

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(City)	(State)	(Zip)							
(Street) MINNEAPOLIS	MN	55413	 4. If Amendment, Date of Original Filed (Month/Day/Year) 08/17/2023 	6. Indiv X	ridual or Joint/Group Filing Form filed by One Rep Form filed by More tha	,			
614 MCKINLEY P	LACE NE				CFO				
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/15/2023	x	Officer (give title below)	Other (specify below)			
1. Name and Address o <u>Hippel James</u>	of Reporting Pers	on*	2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]		tionship of Reporting Pers all applicable) Director	on(s) to Issuer 10% Owner			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	 3. Transac Code (In 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(IIISU. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Restricted Stock Units	(1)	08/15/2023		Α		13,865		(2)	(2)	Common Stock	13,865	\$ <u>0</u>	13,865	D	
Stock Options (Right to Buy)	\$84.61	08/15/2023		Α		37,314		(2)	08/15/2030	Common Stock	37,314	\$ <u>0</u>	37,314	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

2. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Remarks:

This amendment is being filed to correct the number of restricted stock units and performance options being granted.

/s/ Andrew Nick, Attorney-in-Fact 12/14/2023 for James Hippel pursuant to Power of Attorney previously filed Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.